Sign in or Register   Sign in or Register
  |  

Mouse Anti-F5 Recombinant Antibody (CBXF-2766) (CBMAB-F1578-CQ)

This product is a mouse antibody that recognizes F5. The antibody CBXF-2766 can be used for immunoassay techniques such as: ELISA, RIA.
See all F5 antibodies

Summary

Host Animal
Mouse
Specificity
Cattle, Human
Clone
CBXF-2766
Antibody Isotype
IgG1
Application
ELISA, RIA

Basic Information

Immunogen
Purified human Factor V
Specificity
Cattle, Human
Antibody Isotype
IgG1
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Concentration
5 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Target

Full Name
Coagulation Factor V
Introduction
This gene encodes an essential cofactor of the blood coagulation cascade. This factor circulates in plasma, and is converted to the active form by the release of the activation peptide by thrombin during coagulation. This generates a heavy chain and a light chain which are held together by calcium ions. The activated protein is a cofactor that participates with activated coagulation factor X to activate prothrombin to thrombin. Defects in this gene result in either an autosomal recessive hemorrhagic diathesis or an autosomal dominant form of thrombophilia, which is known as activated protein C resistance.
Entrez Gene ID
Human2153
Cattle280687
UniProt ID
HumanP12259
CattleQ28107
Alternative Names
Coagulation Factor V; Coagulation Factor V (Proaccelerin, Labile Factor); Activated Protein C Cofactor; Coagulation Factor V Jinjiang A2 Domain; Proaccelerin, Labile Factor; Factor V Leiden;
Research Area
Central regulator of hemostasis. It serves as a critical cofactor for the prothrombinase activity of factor Xa that results in the activation of prothrombin to thrombin.
Biological Process
Blood circulation Source: GO_Central
Blood coagulation Source: GO_Central
Cellular Location
Secreted
Involvement in disease
Factor V deficiency (FA5D):
A blood coagulation disorder leading to a hemorrhagic diathesis known as parahemophilia.
Thrombophilia due to activated protein C resistance (THPH2):
A hemostatic disorder due to defective degradation of factor V by activated protein C. It is characterized by a poor anticoagulant response to activated protein C resulting in tendency to thrombosis.
Budd-Chiari syndrome (BDCHS):
A syndrome caused by obstruction of hepatic venous outflow involving either the hepatic veins or the terminal segment of the inferior vena cava. Obstructions are generally caused by thrombosis and lead to hepatic congestion and ischemic necrosis. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain and abdominal ascites. Budd-Chiari syndrome is associated with a combination of disease states including primary myeloproliferative syndromes and thrombophilia due to factor V Leiden, protein C deficiency and antithrombin III deficiency. Budd-Chiari syndrome is a rare but typical complication in patients with polycythemia vera.
Ischemic stroke (ISCHSTR):
A stroke is an acute neurologic event leading to death of neural tissue of the brain and resulting in loss of motor, sensory and/or cognitive function. Ischemic strokes, resulting from vascular occlusion, is considered to be a highly complex disease consisting of a group of heterogeneous disorders with multiple genetic and environmental risk factors.
Pregnancy loss, recurrent, 1 (RPRGL1):
A common complication of pregnancy, resulting in spontaneous abortion before the fetus has reached viability. The term includes all miscarriages from the time of conception until 24 weeks of gestation. Recurrent pregnancy loss is defined as 3 or more consecutive spontaneous abortions.
PTM
Thrombin activates factor V proteolytically to the active cofactor, factor Va (formation of a heavy chain at the N-terminus and a light chain at the C-terminus).
Sulfation is required for efficient thrombin cleavage and activation and for full procoagulant activity.
Activated protein C inactivates factor V and factor Va by proteolytic degradation.
Phosphorylated by FAM20C in the extracellular medium.

Andresen, M. S., Sletten, M., Sandset, P. M., Iversen, N., Stavik, B., & Tinholt, M. (2022). Coagulation Factor V (F5) is an Estrogen-Responsive Gene in Breast Cancer Cells. Thrombosis and Haemostasis, 122(08), 1288-1295.

Castoldi, E. (2021). F5‐Atlanta: Factor V‐short strikes again. Journal of Thrombosis and Haemostasis, 19(7), 1638.

Su, K., Wang, L., Wang, M., & Wang, H. (2021). A novel mutation (Ser951LeufsTer8) in F5 gene leads to hereditary coagulation factor V deficiency. Blood Coagulation & Fibrinolysis, 32(2), 140-145.

Lind, S. M. (2021). The role of coagulation factor V in breast cancer: effect on treatment response (Master's thesis, Norwegian University of Life Sciences, Ås).

Tinholt, M., Stavik, B., Tekpli, X., Garred, Ø., Borgen, E., Kristensen, V., ... & Iversen, N. (2020). Coagulation factor V is a marker of tumor-infiltrating immune cells in breast cancer. Oncoimmunology, 9(1), 1824644.

Liu, M., Yang, Y., & Liu, Y. (2020). Identification of a novel variant of F5 gene in a consanguineous pedigree affected with inherited coagulation factor V deficiency. Zhonghua yi xue yi Chuan xue za zhi= Zhonghua Yixue Yichuanxue Zazhi= Chinese Journal of Medical Genetics, 37(5), 505-508.

Tabibian, S., Shiravand, Y., Shams, M., Safa, M., Gholami, M. S., Heydari, F., ... & Dorgalaleh, A. (2019, July). A comprehensive overview of coagulation factor V and congenital factor V deficiency. In Seminars in thrombosis and hemostasis (Vol. 45, No. 05, pp. 523-543). Thieme Medical Publishers.

Paraboschi, E. M., Menegatti, M., Peyvandi, F., Duga, S., & Asselta, R. (2019). Understanding the impact of aberrant splicing in coagulation factor V deficiency. International Journal of Molecular Sciences, 20(4), 910.

Tinholt, M., Garred, Ø., Borgen, E., Beraki, E., Sletten, M., Sahlberg, K. K., ... & Iversen, N. (2018). Coagulation factor V is expressed in tumors and predicts favorable outcome in aggressive breast cancer. Thrombosis Research, 164, S183.

Ask a question We look forward to hearing from you.
0 reviews or Q&As
Loading...
Have you used Mouse Anti-F5 Recombinant Antibody (CBXF-2766)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare